The interplay between hyperglycemia-induced oxidative stress markers and the level of soluble receptor for advanced glycation end products (sRAGE) in K562 cells

Molecular and Cellular Endocrinology

Volumn 393, Issue 1-2, 2014, Pages 179-186

  Shemirani, Farnosh ^a   Yazdanparast, Razieh ^a  

^a UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Advanced glycation end products; Reactive oxygen species; Receptor for advanced glycation end products; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; CATALASE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; RESVERATROL; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL COUNT; CELL GROWTH; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; K562 CELL LINE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

BIOLOGICAL MARKERS; HUMANS; HYPERGLYCEMIA; K562 CELLS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC;

EID: 84904334715     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.05.019     Document Type: Article

References (64)

1. Aebi H. Catalase in vitro. Method Enzymol. 1984, 105:121-126.
2. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 1998, 15(7):539-553.
3. Barlovic D.P., Soro-Paavonen A., Jandeleit-Dahm K.A. RAGE biology, atherosclerosis and diabetes. Clin. Sci. 2011, 121:43-55.
4. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
5. Bhatwadekar A.D., Ghole V.S. Rapid method for the preparation of an AGE-BSA standard calibrator using thermal glycation. J. Clin. Lab. Anal. 2005, 19:11-15.
6. Brownlee M. Negative consequences of glycation. Metabolism 2000, 49:9-13.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
8. Cheng C., Tsuneyama K., Kominami R., Shinohara H., Sakurai S., Yonekura H., Watanabe T., Takano Y., Yamamoto H., Yamamoto Y. Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod. Pathol. 2005, 18:1385-1396.
9. Chung S.S., Ho E.C., Lam K.S., Chung S.K. Contribution of polyol pathway to diabetes-induced oxidative stress. J. Am. Soc. Nephrol. 2003, 14:S233-S236.
10. Daffu G., del Pozo C.H., O'Shea K.M., Ananthakrishnan R., Ramasamy R., Schmidt A.M. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 2013, 14:19891-19910.
11. Deora A.A., Win T., Vanhaesebroeck B., Lander H.M. A redox-triggered ras-effector interaction. Recruitment of phosphatidylinositol 3'-kinase to Ras by redox stress. J. Biol. Chem. 1998, 273:29923-29928.
12. Devangelio E., Santilli F., Formoso G., Ferroni P., Bucciarelli L., Michetti N., Clissa C., Ciabattoni G., Consoli A., Davi G. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic. Biol. Med. 2007, 43:511-518.
13. Drapper H.H., Hadley M. Malondialdehyde determination as index of lipid peroxidation. Method Enzymol. 1990, 186:421-431.
14. Dronavalli S., Duka I., Bakris G.L. The pathogenesis of diabetic nephropathy. Nat. Clin. Pract. Endocrinol. Metab. 2008, 4:444-452.
15. Evans J.L., Goldfine I.D., Maddux B.A., Grodsky G.M. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrinol. Rev. 2002, 23(5):599-622.
16. Fajans S. Diabetes mellitus, definition, classification, tests. Endocrinology 1995, 1411-1422. Saunders Co, USA. third ed. L. Degroat (Ed.).
17. Fu M.X., Knecht K.J., Thorpe S.R., Baynes J.W. Role of oxygen in cross-linking and chemical modification of collagen by glucose. Diabetes 1992, 41(Suppl. 2):42-48.
18. Geroldi D., Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 2006, 13:1971-1978.
19. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93(4):1143-1152.
20. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
21. Hayashi T., Namiki M. Formation of two-carbon sugar fragments at an early stage of the browning reaction of sugar and amine. Agric. Biol. Chem. 1980, 44:2575-2580.
22. Huang J.S., Guh J.Y., Chen H.C., Hung W.C., Lai Y.H., Chuang L.Y. Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J. Cell Biochem. 2001, 81:102-113.
23. Humpert P.M., Papadopoulos G., Schaefer K., Djuric Z., Konrade I., Morcos M., Nawroth P.P., Bierhaus A. SRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm. Metab. Res. 2007, 39:899-902.
24. Hunt J.V., Dean R.T., Wolff S.P. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. Biochem. J. 1988, 256(1):205-212.
25. Ihara Y., Toyokuni S., Uchida K., Odaka H., Tanaka T., Ikeda H., Hiai H., Seino Y., Yamada Y. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. ADA 1999, 48(4):927-932.
26. Jandeleit-Dahm K., Cooper M.E. The role of AGEs in cardiovascular disease. Curr. Pharm. Des. 2008, 14:979-986.
27. Jiang J.M., Wang Z., Li D.D. Effects of AGEs on oxidation stress and antioxidation abilities in cultured astrocytes. Biomed. Environ. Sci. 2004, 17:79-86.
28. Johansen J.S., Harris A.K., Rychly D.J., Ergul A. Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc. Diabetol. 2005, 4(1):5.
29. Katakami N., Matsuhisa M., Kaneto H., Matsouoka T.A., Sakamoto K., Nakatani Y., Ohtoshi K., Hayaishi-Okano R., Kosugi K., Hori M., Yamasaki Y. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: it's possible association with diabetic vascular complications. Diabetes Care 2005, 28:2716-2721.
30. Kumawat M., Pahwa M.B., Gahlaut V.S., Singh N. Status of antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus with micro vascular complications. Open Endocrinol. J. 2009, 3:12-15.
31. Lal M.A., Brismar H., Eklof A.C., Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int. 2002, 61:2006-2014.
32. Lander H.M., Tauras J.M., Ogiste J.S., Hori O., Moss R.A., Schmidt A.M. Activation of the receptor for advanced glycation endproducts triggers a MAP Kinase pathway regulated by oxidant stress. J. Biol. Chem. 1997, 272:17810-17814.
33. LeBel C.P., Ischiropoulos H., Bondy S.C. Evaluation of the probe 2',7'dichlorofluorescein as an indicator of reactive oxygen species formation and oxidative stress. J. Chem. Res. Toxicol. 1992, 5:227-231.
34. Maillard-Lefebvre H., Boulanger E., Daroux M., Gaxatte C., Hudson B.I., Lambert M. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology 2009, 48:1190-1196.
35. Monnier, V., Gerhardinger, C., Marion, M.S., Taneda, S., 1995. In: Cutler, R.G., Packer, L., Bertram, J., Mori, A. (Eds.), Oxidative Stress and Aging, Switzerland, pp. 141-149.
36. Mossine V.V., Linetsky M., Glinsky G.V., Ortwerth B.J., Feather M.S. Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions. Chem. Res. Toxicol. 1999, 12:230-236.
37. Motawi T.M., Abou-Seif M.A., Bader A.M., Mahmoud M.O. Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients. BMC Endocr. Disord. 2013, 13:32.
38. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., Sato A., Imaizumi T. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev. 2007, 23:368-371.
39. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267:14998-15004.
40. Ng Z.X., Chua K.H., Iqbal T., Kuppusamy U.R. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy. Int. J. Mol. Sci. 2013, 14:7480-7491.
41. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790.
42. Odetti P., Traverso N., Cosso L., Noberasco G., Pronzato M.A., Marinari U.M. Good glycaemic control reduces oxidation and glycation end-products in collagen of diabetic rats. Diabetologia 1996, 39:1440-1447.
43. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967, 70(1):158-169.
44. Pick E., Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J. Immunol. Method 1980, 38:161-170.
45. Ramakrishna V., Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 2008, 45:41-46.
46. Ramasamy R., Vannucci S.J., Yan S.S., Herold K., Yan S.F., Schmidt A.M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28R.
47. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., Reiss K., Saftig P., Bianchi M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22:3716-3727.
48. Reznick A.Z., Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Method Enzymol. 1994, 233:357-363.
49. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., Takahashi H. Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. ADA 2003, 52(3):581-587.
50. Santilli F., Bucciarelli L., Noto D., Cefalu A.B., Davi V., Ferrante E., Pettinella C., Averna M.R., Ciabattoni G., Davi G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
51. Santilli F., Vazzana N., Bucciarelli L.G., Davi G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem. 2009, 16:940-952.
52. Schmidt A.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., Clauss M., et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 1992, 267:14987-14997.
53. Schuenstein E., Esterbauer H. Formation and properties of reactive aldehydes. Ciba Found. Symp. 1978, 67:225-244.
54. Soulis-Liparota T., Cooper M.E., Dunlop M., Jerums G. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 1995, 38:387-394.
55. Tam X.H., Shiu S.W., Leng L., Bucala R., Betteridge D.J., Tan K.C. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin. Sci. 2011, 120:81-89.
56. Tanaka Y., Tran P.O., Harmon J., Robertson R.P. A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity. Proc. Natl. Acad. Sci. USA 2002, 99(19):12363-12368.
57. Telci A., Cakatay U., Salman S., Satman I., Sivas A. Oxidative protein damage in early stage Type 1 diabetic patients. Diabetes Res. Clin. Pract. 2000, 50:213-223.
58. Thornalley P., Wolff S., Crabbe J., Stern A. The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions. Biochim. Biophys. Acta 1984, 797:276-287.
59. Umadevi S., Gopi V., Parthasarathy A., Elangovan V. Ameliorative potential of gallic acid on the activation of ROS and down-regulation of antioxidant enzymes in cardiac tissue of rats infused with advanced glycation end products. JAPS 2011, 01(07):189-193.
60. Wolff S.P., Dean R.T. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem. J. 1987, 245(1):243-250.
61. Xu B., Ji Y., Yao K., Cao Y.X., Ferro A. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Clin. Sci. 2005, 109:439-446.
62. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 2005, 11:2279-2299.
63. Yan S.D., Schmidt A.M., Anderson G., Zhang J., Brett J., Zou Y.S., Pinsky D., Stern D. Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J. Biol. Chem. 1994, 269:9889-9897.
64. Yim M.B., Yim H.S., Lee C., Kang S.O., Chock P.B. Protein glycation: creation of catalytic sites for free radical generation. Ann. NY Acad. Sci. 2001, 928:48-53.